Craniomaxillofacial Reconstructive Surgery Track: RhBMP-2 Does Not Pose a Cancer Risk in Maxillofacial Reconstructive Surgery Procedures

Recombinant human bone morphogenetic protein is a mainstay in maxillofacial bone regeneration via in-situ tissue engineering. It represents the signal in the tissue engineering paradigm of the cells-signal-matrix. However, its pleotropic effects of signaling cellular proliferation, migration, differentiation and bone formation in embryologic skeletal development have generated a concern for cancer development or promotion when used in patients. This notion was bolstered in 2013, by a retrospective public data paper in the Journal of Bone and Joint Surgery reporting an 11 to 2 incidence of cancer developing in the rhBMP-2/ACS group as compared to an autogenous graft group.
Source: Journal of Oral and Maxillofacial Surgery - Category: ENT & OMF Authors: Source Type: research